Traci M. Ostertag, M.S., serves as Vice President of Discovery Biology and Operations.  Traci has over 20 years of drug discovery and development experience across oncology, immunology, and metabolic disease indications with expertise in early-stage drug discovery through to clinical development, operations, and R&D strategy.  Prior to Abintus, Traci was a key contributor to establishing Viscient Biosciences’ drug discovery programs and operations.  At Ardea Biosciences, she was a discovery and development team member for Zurampic, which received FDA and EMA approval.  Her industry experience has spanned multiple startups as well as pharma, including Ligand Pharmaceuticals and Takeda.  Traci holds a M.S. in Molecular Virology from San Diego State University.